parameters assessed were leukocyte migration inhibition , response to ppd and oral cancer extract ( oca ) , lymphocyte transformation to pha , circulating antibodies to oca and circulating immune complexes ( cic ) .
C0003241
antibodies
C0003313
circulating immune